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Abstract 
Purpose: This study aim was to compare the effectiveness of the median nerve neural mobilization 
(MNNM) and cervical lateral glide (CLG) intervention versus oral ibuprofen (OI) in subjects who 
suffer cervicobrachial pain (CP).  
Methods: This investigation was a, multicenter, blinded, randomized controlled clinical trial 
(NCT02595294; NCT02593721). A number of 105 individuals diagnosed with CP were enrolled in 
the study and treated in 2 different medical facilities from July to November 2015. Participants were 
recruited and randomly assigned into 3 groups of 35 subjects. Intervention groups received MNNM 
or CLG neurodynamic treatments, and the (active treatment) control group received an OI 
treatment for 6 weeks. Primary outcome was pain intensity reported through the Numeric Rating 
Scale for Pain (NRSP). Secondary outcomes were physical function involving the affected upper limb 
using the Quick DASH scale, and ipsilateral cervical rotation (ICR) using a cervical range of motion 
(CROM) device. Assessments were performed before and 1 hour after treatment for NRSP 
(baseline, 3 and 6 weeks) and CROM (baseline and 6 weeks), as well as only 1 assessment for Quick 
DASH (baseline and 6 weeks).  
Results: Repeated-measures ANOVA intergroup statistically significant differences were shown 
for CP intensity (F(2,72) = 22.343; P < .001; Eta2 = 0.383) and Quick DASH (F(2,72) = 15.338; P < .001; 
Eta2 = 0.299), although not for CROM (F(2,72) = 1.434; P = .245; Eta2 = 0.038). Indeed, Bonferroni´s 
correction showed statistically significant differences for CP intensity (P < .01; 95% CI = 0.22 – 3.26) 
and Quick DASH reduction (P < .01; 95% CI = 8.48 – 24.67) in favor of the OI treatment at all 
measurement moments after baseline.  
Conclusions: OI pharmacologic treatment may reduce pain intensity and disability with respect to 
neural mobilization (MNNM and CLG) in patients with CP during six weeks. Nevertheless, the 
non-existence of between-groups ROM differences and possible OI adverse effects should be 
considered. 











Cervicobrachial pain (CP) is defined as the 
presence of neck pain that radiates or referrers to the 
upper limb that may be derived from neuropathic, 
pathomechanical, and degenerative disorders, as well 
as infections and systemic diseases [1–3]. Early 
descriptions involving CP can be found in the Edwin 
Smith medical papyrus dated 3700 BC [4], never the 
less, recent information regarding the incidence of this 
condition is not available. Most CP studies refer an 
incidence of 83 per every 100.000 individuals based on 
Radhakrishnan et al. [2] findings, accompanied by a 5 
year prevalence of symptoms. 2016 up to date data 
reported by Gangavelli et al. [3] concludes that only 
19.9% of CP cases are truly of neurogenic origin.  
Gold standard diagnosis of CP is achieved by the 
presence of a positive correlation between clinical and 
radiographic pathological findings in a magnetic 
resonance imaging (MRI) procedure [5–8]. Other 
diagnostic methods for this condition are pathologic 
findings in nerve electro conduction evaluations and 
positive outcomes in orthopedic tests: Spurling, upper 
limb (ULT) and distraction test [9–11]. 
First line treatment of CP is done by a 
conservative pharmacological approach, employing 
non-steroidal antiinflammatory drugs (NSAIDs) such 
as oral ibuprofen (OI) (placed among the principal 
NSAIDs prescribed worldwide to treat pain and CP) 
and specific physiotherapy techniques, meanwhile 
surgical procedures are should be reserved for cases 
of life- threatening co-morbidities or disabling pain 
[12–15]. 
Interesting data of over 6 studies concluded the 
presence of nerve trunk mechano-sensibility 
alterations of the cervicobrachial neural components 
during the onset of CP. The presence and desired 
reversal of central sensitization are key elements to be 
considered when selecting a proper treatment method 
for this condition [16–21]. Specific physical therapy 
procedures designed to treat CP are believed to target 
these key elements that produce neuromechanical 
dysfunction and central sensitization. These series of 
procedures include manual orthopedic therapy, dry 
needling, myofascial release and neurodynamic 
maneuvers of cervical contralateral glide (CLG) as 
well as median nerve neural mobilization (MNNM) 
[11,16,22,23]. 
Neurodynamic techniques of CLG and MNMM 
were originally developed by Butler et al., Coppieters 
et al., and Elvery-Hall as provocation test, and 
posteriorly evolved into treatment methods [24–26]. 
These techniques were designed to achieve CP relief 
through controlled mechanical stimulation of the 
median nerve and the brachial plexus. Although the 
entire set of underlying reasons for this pain 
reduction effect is not completely understood, it is 
assumed that prescribed mechanical stimulation of a 
nerve and its surrounding tissue may induce a variety 
of positive neuro-physiologic responses that improve 
pain threshold to stimuli, due to the activation of an 
inhibitory descending nervous system pathway. The 
positive effects derived from the application of 
MNNM and CLG that are linked to pain modulation 
are: changes on the viscoelastic properties of the nerve 
and local musculoskeletal tissue, indirect joint 
mobilization, intraneural pressure and edema 
reduction, dispersion of pro-inflammatory substances 
and an increase in nerve mobility [17,27,28]. 
Both OI and neurodynamic treatments (MNNM 
and CLG) are believed to be effective in treating CP; 
nevertheless, this happens through extremely 
different physiologic pathways, and therefore, both 
treatments present vastly distinctive side effects. An 
OI treatment constitutes an oral intake of a drug, 
originally designed to control pain, fever and 
inflammation. OI hypoalgesic and anti-inflammatory 
effect is achieved by chemical inhibition of the COX 
enzymes that convert arachidonic acid to 
prostaglandin H2 (PGH2), which is then converted by 
other enzymes to several types of mediators of 
inflammation and pain [18,29,30]. 
OI is capable of producing a vast quantity of side 
effects that can be severe in some patients even inside 
the limits of a regular over the counter doses. 
Therefore, OI may not be suitable for treatment in all 
types of subjects who suffer CP. Meanwhile the 
neurodynamic treatment for CP (MNNM and CLG) 
has no important side effect when applied properly, 
with the only exception of a temporary worsening of 
the subjects’ symptomatology. This constitutes a very 
interesting point of comparative effectiveness 
between these two first line treatment alternatives of 
CP [12,17,31]. Additional, comparative randomized 
clinical trials (RCT) regarding MNNM, CLG and OI in 
CP without the mixed combination of other 
treatments are currently non-existent, which by itself 
is stand-alone challenge in regards to proper 
treatment selection for the practicing clinician who 
desires high quality evidence on the neurodynamic 
treatments (MNNM and CLG) level of effectiveness 
when compared to common over the counter 
pharmaceutical treatment for CP [29,32–36].  
Based on the previously exposed rationale, the 
objective of the present study was to compare the pain 
intensity, functionality and cervical range of motion 
effectiveness of the MNNM and CLG neural 
mobilization treatments versus a pharmacological 








This study was a controlled, experimental, 
randomized, multicenter, single-blind clinical trial 
that was performed to establish efficacy between 
treatments. The present investigation had 3 research 
arms (2 active experimental treatment arms and 1 
active control arm) with a 1: 1: 1 allocation radius, 
conducted in Venezuela (in two locations). One of the 
study´s co-authors (FUS, Venezuela) contacted with 
the centers, local physicians and physical therapists 
from Venezuela which were involved in the 
recruitment and outcome measurements. 
Furthermore, FUS was the responsible author to get 
the Ethics committee approval and organize the 
completion of the study. At all times participants and 
researchers were emphasized the need to maintain 
blinding. During the present study, the CONSORT 
and up to date World Medical Association's 
Declaration of Helsinki guidelines were followed. 
Valencia (Venezuela) Polyclinic Center Ethics 
Committee approved this study (code CE0072015, 
CE0072015-2). All subjects gave a written informed 
consent to participate in the present investigation. The 
individual of the Fig 1 and Fig 2 in this manuscript 
has given written informed consent to publish these 
case details. The trial was registered at 
ClinicalTrials.gov (NCT02595294, NCT02593721).  
This study was based on a combination of 2 
approved studies with a deviation of the sample size 
calculation from the original protocols (codes 
CE0072015 and CE0072015 of ethics committee 
approvals; and NCT02595294 and NCT02593721 
number clinical trial registries) in order to include 3 
groups in the study by means of a stratified 
randomization. These changes were performed after 
completion these original protocols and 
communicated to the ethics committee. The authors 
confirm that all ongoing and related trials for this 
drug/intervention are registered. Nevertheless, there 
was a delay in registering this study (October 2015, 
after enrolment of participants started). The trial was 
not prospectively registered, although the recruitment 
began immediately after the Ethics Committee 
approval date (July, 2015). In order to perform the 
recruitment associated to a doctoral process of the 
author FUS, the research process had to be adapted to 
the PhD schedule. Raw data of the demographic data 
and main outcomes measurements is available as S1 
Raw data for all treatment groups. Subjects were 
assigned to 1 of the 3 groups (each group contained 35 
subjects) using restricted block stratified 
randomization through a block computerized 
randomization software.  
Participants 
The study population was composed by subjects 
with medical diagnosis of CP. A total of 144 subjects 
were recruited and evaluated from July to November 
2015. All necessary medical assessments including 
diagnosis and corroboration of pathological findings 
that were present in the MRI study and performed by 
a specialized physician [5–8]. A sample of 105 
participants was considered suitable for recruitment, 
which were divided into three groups of 35 
participants. The enrollment of subjects was 
performed by the specialized physician (internist 
medical doctor) according to the randomization 
scheme generated by the statistical analyst. Group "A" 
contained subjects treated with MNNM, group "B" 
contained subjects treated with OI and group "C" 
those participants treated with CLG. Inclusion criteria 
for participants were the following: Adults aged 18-45 
years of both genders, who presented a signed 
informed consent to participate, a diagnosis of 
unilateral CP confirmed by MRI and Spurling, 
Distraction, and Upper Limb Orthopedic tests [5–11]. 
Exclusion criterions for participating subjects were: 
the presence NSAIDs intake contraindication, the use 
of any type of pain relief treatments at the current 
moment of enrollment, the presence of stenosis due to 
myelopathy, vertebral instability, cognitive impairm-
ent, pregnancy, kinesiophobia (Tampa Scale for 
Kinesiophobia (TSK-11) score > 34.04) [37], spinal 
cord or vertebral surgery, osteoporosis, infections, 
deformities or neoplasia in the medical record 
[29,32–36]. 
Randomization and blinding 
The stratified randomization and allocation to 
trial group protocol were carried out through 
computer software randomized machine-printed 
cards. These cards were then placed inside a series of 
serial numbered non-translucid envelopes, which 
were completely sealed. The printed cards displayed 
an alphabetical letter that corresponded to one of the 3 
groups. Randomization and allocation was designed 
by the data analyst.  
The sealed envelopes were then handled to the 
internist medical doctor who delivered the envelopes 
to the candidates according to schedule. The internist 
medical doctor was blinded to the tested hypothesis 
and group randomization. Subject and physical 
therapist outcome assessor were blinded to the 
randomization, the group allocation, and the tested 
hypothesis; this blinding process was achieved by 




concealing the existence of other groups as well as the 
tested hypothesis. The subject and physical therapist 
outcome assessor were kept blinded after the 
assignment to intervention. The concealment of 
information between subjects and all the investigation 
members played a crucial role in the achievement of 
the study´s blinding process [33].  
Main outcome 
CP intensity was measured through the numeric 
rating scale for pain (NRSP) on intervention sessions 1 
(at baseline), 15 (at 3 weeks) and 30 (at 6 weeks), 
before and 1 hour after the application of the MNNM, 
DLC and OI treatments. CP intensity was considered 
the primary outcome (standard error of measure was 
equal to 1.02) [36,38]. The NRSP consists of a 
horizontal straight line of 11 cm subdivided in 
numbers which are equidistant from 0 to 10, so that 
"0" is equivalent to "total absence of pain" and 10 to 
"greater pain bearable". This scale can be used to 
measure the presence and modulation of pain in the 
upper limb effectively [39]. A change of 1.39 points 
may be considered as a clinical significance [40]. A 
high intraclass correlation coefficient (ICC) between 
the NRSP and visual analog scale (ICC = 0.88) and a 
good inter-rater reliability (kappa coefficient = 0.84) 
were shown [41,42]. 
Secondary outcomes 
Both active cervical range of motion (CROM) 
device and Quick Disabilities of the Arm, Shoulder 
and Hand (DASH) scale results were established as 
the secondary outcomes [36]. Affected upper limb 
function was measured through the Quick DASH 
questionnaire. The Quick DASH is the abridged 
version of the DASH questionnaire. It is validated in 
Spanish and consists of 30 questions [43]. The Quick 
DASH questionnaire was applied only on 
intervention session 1 (at baseline) and 30 (at 6 weeks) 
[36]. Minimum clinically important difference was set 
at 17.1 [44]. The Quick DASH was shown to be an 
acceptable and valid questionnaire with low floor and 
ceiling effects. In addition, high internal consistency 
(Cronbach’s α = 0.92 – 0.95) and test-retest reliability 
(ICC = 0.90 – 0.94) were reported [43,45]. 
Ipsilateral cervical rotation (ICR) was assessed 
using a CROM device on sessions 1 (at baseline) and 
30 (at 6 weeks), before and 1 hour after the application 
of the MNNM, DLC and OI treatments [36]. Standard 
error of measurement ranged from 1.6 to 2.8 degrees 
[46]. This measure can be used for monitoring or to 
assess performance during and after both 
conservative and invasive treatments [47,48]. The 
validity of this tool was determined by means of 
Pearson correlation coefficients between the CROM 
device and the Fastrak motion analysis system which 
ranged from 0.93 to 0.98. Test-retest reliability was 
shown to be good (ICC = 0.89 – 0.98) [46,48]. 
Intervention 
Participants selected in the study were stratified 
randomly assigned to receive one of the 3 proposed 
treatments. The first group ("A") received a 
non-invasive and non-pharmacological intervention 
of MNNM (Fig 1A and 1B), which was applied by a 
physiotherapist on a continuous basis for two minutes 
on five different occasions (five repetitions of 
continuous MNNM application) with one minute of 
rest between every two minutes of continuous 
application of the MNNM technique. The total 
duration of the neural mobilization application was 
six weeks (five interventions per week from Monday 
to Friday) based on a prior study which reported 
improvements in CP intensity and functionality [36]. 
MNNM intervention was implemented following the 
principles of neural mobilization established by Butler 
et al. [24] and Elvery & Hall [26] for the treatment of 
CP and similar to the technique described by De la 
Llave et al. [16]. To begin the procedure of MNNM 
application, the physiotherapist placed the subject in a 
supine position on a stretcher where physical 
therapist held the patient's shoulder in 90º of 
abduction with external rotation during the whole 
process of neural tissue mobilization except in the rest 
intervals. In order to mobilize the cervicobrachial 
neural tissue, an initial treatment position of the 
affected limb was performed, which consisted of 
elbow flexion with wrist and fingers extension, the 
subject's head was placed in a neutral position (Fig 
1A). From the initial position, an elbow extension 
movement was performed with a wrist and finger 
flexion component (Fig 1B), subsequently the upper 
limb was immediately mobilized again, but this time 
the movement led to the initial position of the upper 
limb (flexion of elbow with extension of wrist and 
fingers). The participant might feel as nerve tension as 
reproduction of symptoms during the neural slide 
technique [16]. 
The second group (group "B") received a 
pharmacological treatment of IO in tablets. It was 
indicated by the treating physician who was familiar 
with the use and undesirable effects of IO on CP. The 
physician was in charge of modulating the doses of 
ibuprofen to the tolerance of the patient and in turn 
tried to achieve the desired hypoalgesic effect. The 
starting dose was a single dose of 400 mg / day. Then 
the physician increased the dose linearly every day 
until reaching a maximum of 1200 mg / day. The OI 
was divided into three doses every eight hours [31].  






Fig 1. Initial and final positions of the MNNM slide maneuver. (A) Initial position. (B) Final position. Abbreviation: MNNM, median nerve neural mobilization. 
 
Fig 2. Initial and final positions of the CLG neural slide maneuver. (A) Initial position. (B) Final position. Abbreviation: CLG, cervical lateral glide. 
 
Finally, the third group ("C") received a 
non-invasive neural mobilization treatment using the 
CLG technique (Fig. 2A and 2B), which was applied 
by a physiotherapist on a continuous basis for two 
minutes on five different occasions (five repetitions of 
continuous CLG application) with one minute of rest 
between every two minutes of continuous application 
of the CLG technique. The total duration of the CLG 
application was six weeks ((five interventions per 
week from Monday to Friday)) based on a prior study 
which reported improvements in CP intensity and 
functionality [36]. The CLG intervention was 
implemented following the principles of neural 
mobilization established by Butler et al. [24], Elvery & 
Hall [26] for the treatment of CP and similar to the 
technique extensively described by Allison et al. [17]. 
The CLG technique was applied by means of an initial 
supine positioning of the subject on a stretcher, with 
both elbows in 90º flexion, shoulders in slight 
abduction and both hands resting on the abdomen or 
chest (Fig 2A). The physiotherapist carefully 
stabilized the shoulder in the acromial region with 
one hand while holding the subject's neck and head. 
The gliding technique was performed in a controlled 
and careful way in a contra-lateral direction to the 
affected side until a point prior to the reproduction of 
pain or the perception of a cervical joint barrier that 
will block the sliding movement (Fig 2B) [17,36]. 
Sample size 
The sample size calculation method used in the 
present study was performed through computer 
software available at http://med.unne.edu.ar/ 
biblioteca/calculos/calculadora.htm. The estimated 
sample size was of 105 subjects, at a 95% confidence 
level, an estimated 5% error (with a two-tailed 
hypothesis), a power (1 – β) of 0.90 as well as an 
estimation of improvement in the 50% of the sample. 
The total sample of 144 participants assessed for 
eligibility showed similar sociodemographic data and 
the same diagnosis as well as were evaluated 1 week 
before the start of the study. Therefore, 3 groups of 35 
participants were satisfactory for their comparison. 
Statistical method 
SPSS version 22.0 for Windows (IBM Corp. 
Released 2013. IBM SPSS Statistics for Windows, 
Version 22.0. Armonk, NY: IBM Corp) was used for 
statistical analysis. The statistical tests were 
performed considering a 95% confidence interval (P < 




.05). Only the data collected from subjects who ended 
the trial was processed, since they had to be evaluated 
in terms of pain according to the NRSP scale, the 
Quick DASH scale and the CROM measurement. 
Results were expressed in absolute frequencies, 
percentages, mean, standard deviation (SD) and 95% 
confidence intervals. The Kolmogorov Smirnov test 
was used to test normality. Mean and SD were use to 
describe the age and outcome measurements. The 
gender was described by frequencies and percentages. 
One factor analysis of variance (ANOVA) with the 
Fisher’s F-test was applied to test age differences 
between the groups. Chi square test with the χ2 
statistic was applied to test gender differences 
between treatment groups. Repeated-measures 
ANOVA with 2 factors (considering the significance 
of the Greenhouse-Geisser correction when the 
Mauchly test rejected the sphericity) and Bonferroni´s 
correction were applied to determine the intergroup 
comparison for CP intensity (3 groups x 6 
measurements), range of motion (3 groups x 4 
measurements) and physical function (3 groups x 2 
measurements). Furthermore, the effect size was 
calculated by the Eta2 coefficient. In order to simplify 
the exposure of the repeated measures ANOVA and 
Bonferroni´s correction results, only the values related 
to the interaction of the applied treatments (MNNM 
and CLG versus OI) over the dependent variables 
(pain modulation measured through the NRSP, upper 
limb function measured through the Quick DASH 
questionnaire and ICR assessed through a CROM 
Device) were reported.  
Results 
Demographic data and flow diagram 
Considering the Table 1, demographic data of 
the 3 groups did not show statistically significant 
differences for gender (χ2 = 4.550; P = .103) or age 
(F(16,74) = 1.364; P = .192).  
All subjects were Hispanics. The flow diagram is 
shown in Fig 3. Despite a total sample of 105 subjects 
was initially randomized, only 75 patients were 
finally analysed in the MNNM (n = 24), CLG (n = 25) 
and OI (n = 26) groups.  
 





(n = 24) 
CLG (b) 
(n = 25) 
OI (c) 
(n = 26) 
P – value 
(Statistic) 
Age (y) mean 
± SD 
32.3 ± 3.6 33.3 ± 5.0 30.8 ± 4.2 P = .192* 




13 (54.2) 11 (44.0) 19 (73.1) P = .103† (χ2 = 
4.550) 
Abbreviations: CLG, cervical lateral glide; MNNM = median nerve neural 
mobilization; OI = oral ibuprofen. 
*One factor analysis of variance (ANOVA) with the Fisher’s F-test was applied. 




Fig 3. Participant flow through the trial. Abbreviations: CLG, cervical lateral glide; NSAIDs, non-steroidal antiinflammatory drugs; MNNM, median nerve neural 
mobilization; OI, oral ibuprofen. 






Intergroup statistically significant differences 
were shown for CP intensity with a large effect size 
(F(2,72) = 22.343; P < .001; Eta2 = 0.383). Indeed, 
Bonferroni´s correction showed statistically 
significant differences (P < .01; 95% CI = 0.22 – 3.26) 
for CP intensity reduction in favor of the OI treatment 
at all measurement moments, except for baseline 
comparison (Fig 4). 
Range of motion 
CROM did not show intergroup statistically 
significant difference (F(2,72) = 1.434; P = .245; Eta2 = 
0.038) (Fig 5). 
 
 
Fig 4. CP intensity intergroup comparison during follow-up. Abbreviations: CLG, cervical lateral glide; CI, confidence interval; h, hour; MNNM, median nerve neural 
mobilization; NRSP, numeric rating scale for pain intensity; OI, oral ibuprofen. *According to the P-values obtained by the Bonferroni correction (P < .05/3; significance < .017). 
 
Fig 5. Range of motion intergroup comparison during follow-up. Abbreviations: CLG, cervical lateral glide; CI, confidence interval; CROM, cervical range of motion; h, 
hour; MNNM, median nerve neural mobilization; OI, oral ibuprofen. *According to the P-values obtained by the Bonferroni correction (P < .05/3; significance < .017). 





Fig 6. Physical function intergroup comparison during follow-up. Abbreviations: CLG, cervical lateral glide; CI, confidence interval; h, hour; MNNM, median nerve 
neural mobilization; OI, oral ibuprofen; Quick DASH, Quick Disabilities of the Arm, Shoulder and Hand. *According to the P-values obtained by the Bonferroni correction (P < 
.05/3; significance < .017). 
 
Physical function 
Intergroup statistically significant differences 
were shown for Quick DASH with a large effect size 
(F(2,72) = 15.338; P < .001; Eta2 = 0.299). Indeed, 
Bonferroni´s correction showed statistically 
significant differences (P < .01; 95% CI = 2.86 – 24.67) 
for disability reduction in favor of the OI treatment at 
both measurement moments, except for baseline 
comparison between CLG and OI (Fig 6). 
Discussion 
This novel study provides useful findings for the 
conservative treatment of CP. Despite OI may be 
considered a better treatment than CLG and MNNM 
for pain intensity and disability reduction during 6 
weeks, neural mobilization showed the same ICR and 
may reduce the possibility of side effects [18,29,30]. 
Considering previous literature with a control group, 
neural mobilization was shown to be superior to the 
absence of treatment in reducing pain and increasing 
the affected upper limb function of subjects who 
suffer CP (36). 
Regarding the clinical significance of OI versus 
both neural mobilizations (MNNM and CLG), the 
main outcome only reached the minimum clinical 
significance of 1.39 points for the NRSP at 1 hour after 
treatments, but not for the rest of primary outcome 
measurements (Fig 4) [40]. Nevertheless, the 
minimum clinically important difference of 17.1 for 
Quick DASH was reached between CLG and OI 
treatments, although not between MNNM and OI 
interventions (Fig 6) [44]. Considering neural 
mobilization treatments, Salt et al. showed that the 
addition of a lateral-glide mobilization to a 
self-management program did not produce pain 
intensity or functionality improvements in patients 
with chronic CP during 6 weeks and may result in 
higher health-care costs [49]. Nevertheless, CLG 
provided pain intensity and functionality 
improvements with respect to a waiting-list control of 
patients with CP [36]. Furthermore, Nee et al. 
supported that neural tissue management may 
provide immediate clinically relevant benefits in pain 
and function with no evidence of harmful effects in 
participants with CP [29]. During the process of 
results analysis a significant discrepancy was 
determined about the effectiveness of OI in the 
treatment of CP. Therefore, OI may not produce a 
significant effect over CP, according to Sheather-Reid 
& Cohen [14]. It is important to state that although OI 
is recommended worldwide for the treatment of CP 
[30], this discrepancy may be a direct consequence of 
the used 800 mg / day dose. This dose of 800 mg / 
day is considered a dosage significantly lower than 
the recommended 1200 mg / day to achieve an 




appropriate analgesic-anti-inflammatory effect [50]. 
Despite OI may produce lower percentage of side 
effects than other pharmacologic treatments such as 
clonidine (74%) or codeine (69%), up to 28% of 
patients may suffer from sedation, dizziness, and 
other side effects [51]. 
Limitations 
The main study limitations were the lack of a 
placebo or control group and the high loss to 
follow-up which provided a final sample size of 75 
participants while the sample size calculation 
determined at least 105 participants. The retrospective 
trial registry should be considered, and futures 
studies should be registered prospectively. 
Furthermore, Bonferroni´s correction showed 
statistically significant differences between MNNM 
and OI groups for Quick DASH scores at baseline (Fig 
6). Therefore, the results of this study should be 
considered with caution. Indeed, side effects were not 
analyzed and should be considered due to the 
presence of adverse effects in the OI group (Fig 3) [30]. 
Finally, the musculoskeletal or neuropathic origin of 
CP suffered by the subjects was not established and 
may clearly influence the results [52]. According to 
Gangavelli et al., only 19.9% of CP cases may be 
consequence of neurogenic origin [3]. In addition, 
pain catastrophizing or beliefs may alter the 
follow-up, outcome measurements and treatments 
effectiveness [53,54]. 
Conclusion 
In conclusion, OI pharmacologic treatment may 
reduce pain intensity and disability with respect to 
neural mobilization (MNNM and CLG) in patients 
with CP during six weeks. Nevertheless, the 
non-existence of between-groups ROM differences 
and possible OI adverse effects should be considered.  
Clinical Trial Registry 
The trial was registered at ClinicalTrials.gov 
(NCT02595294, NCT02593721). 
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